Other Search Results
https://www.sec.gov/Archives/edgar/data/1528356/000121390024021984/0001213900-24-021984.txt

GENIE ENERGY LTD., GENIE ENERGY LTD. ; By:, /s/ Michael Stein ; Name:, Michael Stein ; Title:, Chief Executive Officer

https://www.sec.gov/Archives/edgar/data/1744489/000095015724000539/0000950157-24-000539.txt

Disclaimer ; Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s expectations; beliefs; plans; strategies; investments; financial performance; expected benefits of new initiatives; content, products, experiences or service offerings (including timing and nature); priorities or performance; businesses and assets; future investments and crea...

https://www.sec.gov/Archives/edgar/data/1163302/000110465922067883/0001104659-22-067883.txt

EX-10.1 2 tm2217179d1_ex10-1.htm EXHIBIT 10.1 ; Exhibit 10.1 · Execution Version · SIXTH AMENDED AND RESTATED CREDIT AGREEMENT · dated as of May 27, 2022 · among · UNITED STATES STEEL CORPORATION · THE LENDERS PARTY HERETO · THE LC ISSUING BANKS PARTY HERETO and · JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent · JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., WELLS FARGO BANK, NATIONAL ASSOCIATION, and · BARCLAYS BANK PLC, as Joint Lead Arrangers an...

https://www.sec.gov/Archives/edgar/data/1750/000110465916093792/0001104659-16-093792.txt

Item 7.01 Regulation FD Disclosure · AAR CORP.’s Vice President, Chief Financial Officer and Treasurer, Michael J. Sharp, presented at the Cowen and Company 37th Annual Aerospace/Defense & Transportation Conference on Thursday, February 4, 2016 in New York City. Attached as Exhibit 99.1 are the slides used by Mr. Sharp in his presentation. The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of t...

https://www.sec.gov/Archives/edgar/data/937136/000110465916146047/0001104659-16-146047.txt

Item 1.01 Entry into a Material Definitive Agreement · On September 21, 2016, Hyperdynamics Corporation (“Hyperdynamics,” the “Company,” “we” or “us”), through its wholly-owned subsidiary, SCS Corporation (“SCS”) received an implementing Presidential Decree from the Republic of Guinea authorizing a Second Amendment (the “Second Amendment”) to the Hydrocarbon Production Sharing Contract, dated September 22, 2006, between SCS and the Republic of Guinea, as amended on Marc...

https://www.sec.gov/Archives/edgar/data/51143/000110465919021671/0001104659-19-021671.txt

Item 2.02. Results of Operations and Financial Condition. The registrant’s press release dated April 16, 2019, regarding its financial results for the periods ended March 31, 2019, including consolidated financial statements for the periods ended March 31, 2019, is Exhibit 99.1 of this Form 8-K. In an effort to provide investors with additional information regarding the company’s results as determined by generally accepted accounting principles (GAAP), the company has disclosed in the attach...

https://www.sec.gov/Archives/edgar/data/1048911/000110465920088330/0001104659-20-088330.txt

0001104659-20-088330.txt : 20200730 0001104659-20-088330.hdr.sgml : 20200730 20200730180518 ACCESSION NUMBER: 0001104659-20-088330 CONFORMED SUBMISSION TYPE: FWP PUBLIC DOCUMENT COUNT: 24...

https://www.sec.gov/Archives/edgar/data/315189/000110465912009955/0001104659-12-009955.txt

Items 2.02 · and 8.01 Results of Operations and Financial Condition and Other Events. The following consists of Deere & Company’s press release dated February 15, 2012 concerning First Quarter of fiscal 2012 financial results and supplemental financial information filed as Exhibit 99.1 to this report and incorporated by reference herein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits · (99.1) Press release and supplemental financial information (Filed herewith) · Items 2.02 .....

https://www.sec.gov/Archives/edgar/data/1720893/000110465919000498/0001104659-19-000498.txt

Item 7.01 Regulation FD Disclosure. On January 3, 2019, BioXcel Therapeutics, Inc. (the “Company”) held an investor conference call and discussed the results of the study described in Item 8.01 below and the Company’s BXCL501 program. In connection with the investor call, the Company prepared presentation materials (“the Presentation Materials”), a copy of which are furnished as Exhibit 99.1 to this current report on Form 8-K. The call will be available via a live, listen-only webcast ...

0001104659 17 014730 txt

Item 7.01 Regulation FD Disclosure. Exhibit 99.1 contains IBM’s presentation materials for the morning session of IBM’s Investor Briefing on March 7, 2017. The information in this Item 7.01, including the corresponding Exhibit 99.1, is being furnished with the Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”). These materials may contain forward-looking statements under the Private Securities Litigation R...

Copyright © www.babybloodtype.com. All rights reserved.
policy sang_list